Replies to post #222742 on NorthWest Biotherapeutics Inc (NWBO)

[exwannabe]

Marz is referring to the link from hope that he replied to. It did not say anything close to marz's assertion. Here is the conclusion:

The interim report from the first Phase III trial of DCV in newly diagnosed GBM confirms safety and feasibility and suggests longer than expected survival with DCV. While we eagerly await the final results from the study and results from other Phase III studies, there is need to further explore the optimal combination of immune-based therapies, ideal integration of these therapies into the current standard of care, and responder phenotypes to identify patients who are most likely to benefit from the therapy.

For those who do not know clinical trial jargon, "suggests" means data that is encouraging but does not prove anything and requires follow up to establish effect.

I would also note it is eagerly expecting data from other P3 trials of DCV (which is how they abbriviated DCVa-L) and see a need to further explore.